Samsung Chairman Lee Jae-yong Reclaims Top Spot as South Korea’s Billionaire Wealth Hits $20 Billion Growth

Samsung's Lee Jae-yong reclaims his title as South Korea's richest person as the top five billionaires see a $20.1 billion wealth surge in 2026.

By: AXL Media

Published: Apr 19, 2026, 11:56 AM EDT

Source: Information for this report was sourced from VnExpress

The Resurgence of the Samsung Dynasty

Lee Jae-yong, the 57-year-old executive chairman of Samsung Electronics, has officially reclaimed his status as South Korea's wealthiest individual. Over the past year, Lee’s net worth experienced an unprecedented increase, rising from $7.8 billion to $21.6 billion as of late March 2026. This nearly threefold jump in wealth marks Lee as the year's largest gainer in dollar terms. The surge is attributed to a significant rebound in Samsung’s memory chip division following a global semiconductor shortage and a lucrative $16.5 billion agreement with Tesla for the production of artificial intelligence chips.

Private Equity Stability Amidst Shifting Ranks

Michael Byung-ju Kim, the 62-year-old co-founder of MBK Partners, moved to the second position on the rich list despite a modest increase in his personal fortune. Kim’s wealth grew from $9.5 billion to $9.9 billion over the last year. As a former Fulbright Scholar with a background at major global firms like Goldman Sachs, Kim has established MBK Partners as a dominant force in Asian private equity, currently managing over $30 billion in assets. His firm recently demonstrated its market influence by raising $5.5 billion for an Asia-focused buyout fund in October.

The Rise of Self-Made Biopharmaceutical Wealth

Seo Jung-jin, the 68-year-old chairman of Celltrion, moved up to third place with a net worth that grew to $8.1 billion from $6.3 billion. Seo’s career trajectory is notable for its self-made origins, having founded the biopharmaceutical firm in 2002 after the bankruptcy of his previous employer. Despite a brief retirement, Seo returned to lead Celltrion, which saw its share value rise by 30% over the last year. His fortune reflects the success of Celltrion's specialized treatments for cancer and rheumatoid arthritis as the company continues its global expansion.